Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bonesupport Holding AB (publ)
  6. News
  7. Summary
    BONEX   SE0009858152

BONESUPPORT HOLDING AB (PUBL)

(BONEX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BONESUPPORT : receives "breakthrough device designation" for CERAMENT G for the indication trauma

06/17/2021 | 04:01am EST

Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT(TM), an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting product CERAMENT G has been categorized as a breakthrough device for the indication trauma by the US Food and Drug Administration (FDA).

The categorization "breakthrough device" can be assigned to products that are considered to provide a more effective treatment of severe disease states, where there is no comparable equivalent on the market. The categorization is intended to expedite the regulatory review of medical devices so that patients receive faster access to new treatment options.

"We will submit a regulatory application including trauma by the end of 2021. The decision from the FDA is of course important regarding the upcoming reimbursement process and with which priority our application will be processed," said Emil Billbäck, CEO of BONESUPPORT.

CERAMENT G has been classified as a breakthrough device for the indication osteomyelitis (bone infection) since March 2020 and BONESUPPORT is currently working to supplement previously submitted application, with the aim of reaching a potential approval for bone infection during the first quarter of 2022. A potential approval for the indication trauma may become effective at the end of 2022.

 

For more information contact:

BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT(TM)

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

https://news.cision.com/bonesupport-holding-ab/r/bonesupport-receives--breakthrough-device-designation--for-cerament-g-for-the-indication-trauma,c3369484

https://mb.cision.com/Main/16090/3369484/1433426.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about BONESUPPORT HOLDING AB (PUBL)
01/13BONESUPPORT signs distribution agreement with OrthoPediatrics
AQ
01/13Bonesupport Signs Distribution Agreement with OrthoPediatrics
CI
2021Change in number of shares and votes in BONESUPPORT Holding AB (publ)
AQ
2021Change in number of shares and votes in BONESUPPORT Holding AB (publ)
AQ
2021Bonesupport Holding AB Reports Earnings Results for the Third Quarter and Nine Months E..
CI
2021Financials
PU
2021BONESUPPORT Holding AB (publ) - Publishes Q3 2021 Interim report
AQ
2021BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2021 Invitation to conference c..
PU
2021BONESUPPORT HOLDING AB (publ) - Interim Report Q3 2021 Invitation to conference call an..
AQ
2021BONESUPPORT : appoints Michael Wrang Mortensen to EVP R&D and Operations
AQ
More news
Financials
Sales 2021 216 M 23,9 M 23,9 M
Net income 2021 -78,7 M -8,73 M -8,73 M
Net cash 2021 241 M 26,8 M 26,8 M
P/E ratio 2021 -32,1x
Yield 2021 -
Capitalization 2 513 M 279 M 279 M
EV / Sales 2021 10,5x
EV / Sales 2022 7,58x
Nbr of Employees 91
Free-Float -
Chart BONESUPPORT HOLDING AB (PUBL)
Duration : Period :
Bonesupport Holding AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BONESUPPORT HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 38,40 SEK
Average target price 67,50 SEK
Spread / Average Target 75,8%
EPS Revisions
Managers and Directors
Emil Billbńck Chief Executive Officer
Hakan Johansson Chief Financial Officer
Erling Lennart Johansson Chairman
Michael Diefenbeck Chief Medical Officer & EVP-Medical Affairs
Michael Wrang Mortensen EVP-Research, Development & Operations
Sector and Competitors
1st jan.Capi. (M$)
BONESUPPORT HOLDING AB (PUBL)-12.73%279
CSL LIMITED-5.06%95 466
WUXI BIOLOGICS (CAYMAN) INC.-0.27%49 958
SAMSUNG BIOLOGICS CO.,LTD.-5.87%47 262
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.26%35 151